Lepu Medical Technology (Beijing) Co Ltd

Lepu Medical Technology (Beijing) Co Ltd maintains a debt-to-equity ratio of 0.41, indicating a relatively conservative capital structure with a strong equity base. The company's liquidity position is characterized by a current ratio of 2.01, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow of 327.25 million CNY is modest relative to its operating cash flow of 1.52 billion CNY, indicating some reinvestment or capital allocation pressure. The company's profitability is reflected in a return on equity (ROE) of 5.97% and a return on assets (ROA) of 3.68%. These figures are in line with the industry's typical performance metrics, which emphasize gross margin and operating margin as key indicators of competitive strength. Lepu Medical's gross profit of 4.04 billion CNY on revenue of 6.48 billion CNY suggests a healthy gross margin, though the operating income of 1.22 billion CNY indicates some pressure from operating expenses. Lepu Medical's revenue is concentrated in the cardiovascular medical devices segment, which constitutes the majority of its business. The company's geographic exposure is primarily within China, with no significant international revenue disclosed in the latest financials. This concentration may expose the company to regulatory and market risks specific to the Chinese healthcare sector. The company's growth trajectory is modest, with no specific revenue growth rates provided in the latest financial data. Analysts have assigned a mean price target of 20.25 CNY and a median price target of 20.64 CNY, with a mean recommendation of 2.00 (1=strong buy, 5=strong sell). The company's capital expenditure of -643.06 million CNY suggests a net reduction in long-term assets, which may indicate a strategic shift or cost-cutting initiative. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights a potential liquidity constraint. The company's dilution potential is low, with no significant dilution sources identified in the latest filings or transcripts. Recent events, including analyst estimates and price targets, suggest a cautiously optimistic outlook from the investment community. The company has not disclosed any major recent filings or transcripts that would indicate significant operational or strategic changes.